Clinical trials
Rejection clinical trials
Below are recruiting rejection clinical trials, each written for real people, not researchers. We’re tracking 102 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06801886Enrolling by invitationPhase 3
Silymarin for better kidney transplant success
This trial tests if adding silymarin (a milk thistle extract) to standard anti-rejection medicines helps protect the new kidney from damage. It may improve how well the transplanted kidney works over time.
MartinAges Any age - NCT06777823Recruiting
Social media and mental health study for girls aged 10-11
This study looks at how social media affects the mental health of girls going through puberty. It tests whether sensitivity to rejection and puberty stage make some girls more vulnerable to social media experiences.
St Louis, MissouriAges 10 years+ - NCT06474273RecruitingPhase 3
Treating acute rejection after a kidney or kidney-pancreas transplant
This study compares two ways of treating acute rejection (when the immune system attacks the new organ) in people who have had a kidney or combined kidney-pancreas transplant. It looks at whether adding a different approach helps protect the transplant long-term.
Lambton, New South WalesAges 2 years+ - NCT05285878Enrolling by invitationPhase 2
Fingolimod to protect kidney function after kidney transplant
This trial tests whether fingolimod can reduce kidney scarring and preserve kidney function after a new kidney transplant. It focuses on people who are in the early period after transplant who may be at risk for scarring in the kidney.
Houston, TexasAges 18–65 - NCT04837339Recruiting
Testing markers to predict problems after lung transplant
This study looks for lab “clues” that can help predict how well someone’s lungs will do after a lung transplant. It may help doctors spot transplant-related problems earlier so care can be planned sooner.
SuresnesAges 15 years+ - NCT05994274Recruiting
Heart transplant, cholesterol, and organ rejection study
This study looks at whether changes in blood fats (cholesterol and triglycerides) after a heart transplant are linked to the risk of organ rejection. It may help doctors better monitor and protect your new heart.
WuhanAges 18 years+ - NCT05600634Recruiting
Monitoring skin graft to spot rejection after kidney transplant
This study follows people after a kidney transplant to see if a small skin graft can help detect early signs of acute rejection. It may help your care team notice rejection sooner and adjust treatment earlier.
Xi'an, ShannxiAges 18–60 - NCT03955172Recruiting
Test of everolimus to reduce transplant rejection
This trial studies whether everolimus can improve outcomes for people whose kidney transplant biopsy shows signs of a specific type of immune attack. It focuses on patients without certain antibodies and with particular biopsy findings, aiming to prevent rejection-related injury while balancing medication side effects.
LyonAges 18 years+ - NCT06112951Recruiting
ECP treatment for early signs of lung transplant rejection
This trial tests whether a therapy called extracorporeal photopheresis (ECP) can stop early, silent rejection in lung transplant patients. It is for people who have developed donor-specific antibodies but still have normal lung function.
ViennaAges 18 years+ - NCT07770659Recruiting
Using MRI to detect early heart transplant rejection
This study tests whether a heart MRI can detect early signs of organ rejection after a heart transplant. If successful, it could reduce the need for frequent biopsies.
Little Rock, ArkansasAges 6–25 - NCT07689578RecruitingPhase 4
Testing a new immunotherapy for chronic kidney transplant rejection
This study tests a new treatment called BiTE (a type of immunotherapy that helps your immune cells attack harmful antibodies) for people whose transplanted kidney is being damaged by chronic active antibody-mediated rejection. The goal is to see if it can safely slow or stop this damage.
Chengdu, SichuanAges 18 years+ - NCT07673536Recruiting
Heart transplant monitoring with extracellular vesicles
This study uses tiny particles called extracellular vesicles (which cells release) to check for signs of organ rejection after a heart transplant, aiming for a safer and less invasive alternative to biopsies.
Berlin, State of BerlinAges 18 years+ - NCT07663669Recruiting
Photopheresis for antibody-mediated rejection in kidney transplant
This study looks at how well extracorporeal photopheresis (a treatment that filters and treats your blood with light) works for kidney transplant patients who have antibody-mediated rejection (when your immune system attacks the new kidney). It may help doctors understand if this treatment can stop the rejection.
BesançonAges 18 years+ - NCT07641426RecruitingPhase 1/Phase 2
CID-103 Treatment for Kidney Transplant Rejection
This study tests an experimental drug called CID-103 to treat antibody-mediated rejection (ABMR), a type of immune response that damages transplanted kidneys. The drug targets immune cells that attack the transplant, and researchers hope it may help preserve kidney function and prevent transplant failure.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06734013Recruiting
Genetic testing to help diagnose liver transplant rejection
This study looks at whether genetic testing of a tissue sample (biopsy) can help doctors more accurately diagnose rejection after a liver transplant. It is for people who have already been diagnosed with rejection and have a stored tissue sample available.
BolognaAges 18 years+ - NCT07531784Recruiting
Blood Test to Detect Heart Rejection After Transplant
This Swedish study tests whether a simple blood test can detect early signs that your body is rejecting a transplanted heart. The test looks for DNA fragments in your blood that may signal rejection before symptoms appear, potentially helping doctors catch problems sooner.
StockholmAges 18 years+ - NCT07516379Recruiting
Understanding Lung Rejection After Transplant
This study follows people with serious lung disease before and after lung transplant to understand how rejection happens and what warning signs to watch for. By studying your blood, tissue samples, and imaging, researchers hope to better predict and prevent transplant rejection.
Bethesda, MarylandAges 18–75 - NCT07444489Enrolling by invitationPhase 3
Long-term safety of felzartamab for kidney transplant rejection
This study checks the long-term safety of felzartamab for people who have had a kidney transplant and are dealing with antibody-mediated rejection or signs of inflammation in the kidney. It's for those who were already in a previous study and took at least one dose of felzartamab.
Los Angeles, CaliforniaAges 18–75 - NCT07275541Recruiting
Platelet test for early kidney rejection diagnosis
This study tests whether a simple blood test that looks at platelet behavior can help doctors diagnose acute rejection after a kidney transplant. Early detection of rejection may lead to faster treatment and better outcomes.
MartinAges 18 years+ - NCT04702022Recruiting
Extra PET scan to check for silent kidney transplant rejection
This study tests whether an additional PET scan can help detect and guide treatment for “subclinical” (silent) rejection in people with kidney transplants. It may help doctors spot problems earlier and manage them more appropriately.
Liège, LiègeAges 18 years+ - NCT07134491Recruiting
B Cells in Kidney Transplant Rejection Study
This study looks at certain immune cells (B cells) in the blood and kidney to better understand antibody-mediated rejection in kidney transplant patients. It might help doctors find new ways to diagnose or treat this type of rejection.
ParisAges 18 years+ - NCT07081126Recruiting
Daratumumab for late antibody-mediated rejection in kidney transplant
This trial tests whether daratumumab can help treat a type of rejection that happens more than a year after a kidney transplant. It may be an option for people who have biopsy-proven antibody-mediated rejection and new donor-specific antibodies.
MartinAges 18 years+ - NCT07053462RecruitingPhase 1/Phase 2
Gene-edited kidney transplant to lower rejection risk
This trial tests a specially edited donor kidney designed to reduce the chance of rejection, especially for people with high sensitivity to donor kidneys. If it works, it could make more kidneys available for those who have a hard time finding a match.
Beijing, ChangpingAges 16–85 - NCT07053488RecruitingPhase 1/Phase 2
Gene-edited liver transplant to lower rejection risk
This trial tests a liver transplant using a donor organ that has been gene-edited to reduce the risk of rejection. It may help people who need a liver transplant and are not a perfect tissue match with their donor.
Beijing, ChangpingAges 16–85
Hear when a new Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for rejection?
- Yes. Clin2 currently lists 102 recruiting rejection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a rejection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a rejection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.